What is this ingredient? Myo‑inositol is a naturally occurring carbocyclic sugar that functions as a structural basis for inositol phosphates and phosphatidylinositol phosphates—key components of cell membranes and intracellular signaling. It acts as a “second‑messenger” building block for insulin, gonadotropin, and thyroid‑stimulating hormone signaling, which is why it is widely studied in insulin‑resistance and reproductive contexts. In randomized trials and meta‑analyses in women with polycystic ovary syndrome (PCOS), myo‑inositol significantly improves insulin resistance (HOMA‑IR), fasting glucose and insulin, and some reproductive hormone parameters compared with placebo or metformin alone ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30608001/?utm_source=openai)).

Myo‑inositol also contributes to better ovulatory function and oocyte quality when used alone or, especially, in physiological combination with D‑chiro‑inositol (often at a 40:1 ratio) in PCOS and IVF populations ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31298405/?utm_source=openai)). Emerging data in pregnancy show that myo‑inositol supplementation can reduce the incidence of gestational diabetes and improve insulin sensitivity in at‑risk women ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35575290/?utm_source=openai)).

Why include it in this formula? From its name and ingredients—myo‑inositol, D‑chiro‑inositol, omega‑3 powder, magnesium glycinate, zinc, and vitamin D3—the “Inositol - 120” product is clearly designed to support metabolic, hormonal, and possibly reproductive health, with a strong emphasis on insulin sensitivity and ovarian function. Within this design, myo‑inositol is the primary "insulin‑signaling and ovarian" pillar. It supplies the main inositol isomer used as an intracellular second messenger for insulin, helping to improve glucose handling and HOMA‑IR in insulin‑resistant states ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/30608001/?utm_source=openai)).

In combination with D‑chiro‑inositol, myo‑inositol helps approximate the physiological ovarian ratio shown to restore ovulation and normalize key endocrine markers in PCOS women ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31298405/?utm_source=openai)). Magnesium and zinc further support insulin signaling and reproductive function, omega‑3s add anti‑inflammatory and cardiometabolic benefits, and vitamin D3 contributes to hormonal and immune balance. Together, this positions myo‑inositol as the central signaling nutrient around which the rest of the formula is built, translating micronutrient and fatty‑acid support into more efficient metabolic and reproductive pathways.

What is this ingredient? D‑Chiro‑inositol (DCI) is one of the main stereoisomers of inositol and functions as a secondary messenger in insulin signaling. It is generated from myo‑inositol via an insulin‑dependent epimerase and participates in intracellular cascades that regulate insulin secretion, mitochondrial respiratory chain activity, and glycogen storage [6]. Because of these roles, DCI has been investigated as an insulin sensitizer in conditions marked by metabolic dysfunction, such as PCOS, obesity, and gestational diabetes.

In human adipocytes, D‑chiro‑inositol modulates the expression of insulin‑related proteins and promotes late‑stage adipocyte differentiation without impairing cell viability, supporting its direct role in insulin signal transduction and glucose handling [6]. Clinical and translational work suggests that physiological combinations of myo‑inositol and D‑chiro‑inositol can restore more normal ovarian steroidogenesis and improve endocrine and metabolic parameters in PCOS models and patients [2,8].

Why include it in this formula? The “Inositol - 120” product combines myo‑inositol, D‑chiro‑inositol, omega‑3 powder, magnesium glycinate, zinc, and vitamin D3. This constellation clearly targets insulin sensitivity, metabolic balance, and reproductive or cycle‑related health. Within this architecture, D‑chiro‑inositol is the "insulin‑effector and ovarian steroidogenesis" partner to myo‑inositol. While myo‑inositol primarily supports FSH signaling and oocyte quality, DCI is especially important for modulating aromatase activity and androgen/estrogen synthesis within the ovary [2,3].

Preclinical work in a murine PCOS model and clinical trials in women with PCOS show that combining myo‑inositol and D‑chiro‑inositol in a physiological 40:1 ratio improves ovulation, normalizes key hormones (FSH, LH, estradiol, free testosterone), and enhances insulin resistance indices compared with other ratios or placebo [2,7,8]. Additional studies report improved lipid profiles and reduced cardiovascular risk markers with this combined therapy [4]. In this formula, D‑chiro‑inositol completes the inositol pair that underpins insulin signaling and ovarian steroidogenesis, while omega‑3s, magnesium, zinc, and vitamin D3 provide supportive metabolic, inflammatory, and endocrine co‑factors around that core.

References

• [2] Inositol restores appropriate steroidogenesis in PCOS ovaries both in vitro and in vivo experimental mouse models
• [4] The combined therapy myo‑inositol plus D‑chiro‑inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients
• [6] D‑Chiro‑Inositol regulates insulin signaling in human adipocytes
• [7] The 40:1 myo‑inositol/D‑chiro‑inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
• [8] A combined therapy with myo‑inositol and D‑chiro‑inositol improves endocrine parameters and insulin resistance in PCOS young overweight women

What is this ingredient? Omega 3 Powder is a stabilized, powdered form of omega‑3 fatty acids, typically providing EPA and/or DHA from marine or algal sources in a matrix suitable for capsules or drink mixes. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long‑chain polyunsaturated fats that incorporate into cell membranes, where they influence membrane fluidity, receptor function, and the balance of lipid mediators derived from omega‑3 versus omega‑6 pathways.

Omega‑3s are widely recognized for their roles in supporting cardiovascular and metabolic health, helping to lower triglycerides, modestly improve blood pressure, and shift eicosanoid production toward less inflammatory species when taken regularly as part of a balanced diet. They also contribute to normal brain and retinal function and may support mood and cognitive performance in some populations.

Why include it in this formula? The “Inositol - 120” product combines myo‑inositol, D‑chiro‑inositol, omega 3 powder, magnesium glycinate, zinc, and vitamin D3. This constellation points to a focus on insulin sensitivity, cycle or reproductive balance, and overall metabolic wellness. Within this architecture, Omega 3 Powder acts as the "membrane and inflammatory‑tone" pillar. While the inositols directly target insulin second‑messenger systems and ovarian steroidogenesis, omega‑3 fatty acids help normalize triglycerides, improve cell‑membrane composition in metabolic tissues, and support a more favorable inflammatory milieu.

This is particularly relevant in insulin‑resistant states, where low‑grade inflammation and altered lipid profiles often coexist with disrupted ovarian function. By pairing omega‑3s with magnesium and zinc (which support insulin signaling and hormone production) and vitamin D3 (which modulates endocrine and immune pathways), the formula goes beyond signaling alone. The powdered omega‑3 component helps ensure that the inositol‑driven improvements in glucose and hormone signaling occur in cells whose membranes, lipid mediators, and cardiometabolic context are also moving in a healthier direction.

What is this ingredient? Magnesium glycinate is a chelated form of magnesium in which the mineral is bound to the amino acid glycine. Once absorbed, it delivers elemental magnesium for use throughout the body. Magnesium is a cofactor for more than 300 enzymes involved in ATP production, glucose and insulin handling, nerve conduction, and muscle relaxation. Low magnesium status is common in people with insulin resistance and metabolic syndrome, and is associated with higher fasting glucose, higher HOMA‑IR, and a greater likelihood of prediabetes or type 2 diabetes in observational and intervention studies [([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21205110/?utm_source=openai))–([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15223977/?utm_source=openai))].

Randomized, double‑blind, placebo‑controlled trials in hypomagnesaemic or insulin‑resistant individuals show that oral magnesium supplementation can significantly improve fasting glucose and HOMA‑IR, and in some cases triglycerides and HDL‑cholesterol, compared with placebo [([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15223977/?utm_source=openai)),([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25937055/?utm_source=openai))]. Not all studies in all populations replicate these benefits, but the weight of evidence supports a role for adequate magnesium in maintaining insulin sensitivity and metabolic balance [([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/21205110/?utm_source=openai)),([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24084051/?utm_source=openai))].

Why include it in this formula? The “Inositol - 120” product combines myo‑inositol, D‑chiro‑inositol, omega‑3 powder, magnesium glycinate, zinc, and vitamin D3. This clearly targets insulin resistance, metabolic health, and often, inositol‑related uses such as PCOS or cycle support. Within this architecture, magnesium glycinate is the "electrolyte and insulin‑cofactor" pillar. While myo‑ and D‑chiro‑inositol act as second‑messenger precursors for insulin and ovarian signaling, magnesium is required for the activity of many kinases and enzymes in the insulin‑signaling cascade, and for proper glucose transport and phosphorylation.

Using a glycinate chelate supports gentle, well‑tolerated absorption, which is especially important for long‑term use. Randomized trials in insulin‑resistant, prediabetic, or metabolic‑syndrome subjects with low magnesium show that correcting magnesium status improves fasting glucose and HOMA‑IR, reinforcing magnesium’s place alongside inositols in any formula aimed at restoring metabolic flexibility [([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/15223977/?utm_source=openai)),([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25937055/?utm_source=openai))]. Paired with zinc and vitamin D3—which also influence insulin and reproductive hormones—and omega‑3s for inflammatory tone, magnesium glycinate helps ensure that the cellular environment is biochemically ready to respond to the improved signaling driven by inositol.

What is this ingredient? Zinc citrate is a supplemental form of zinc in which the mineral is bound to citric acid. Zinc is an essential trace element required as a structural or catalytic cofactor for hundreds of enzymes and transcription factors that regulate DNA and protein synthesis, cell division, antioxidant defense, and immune function. In metabolic and reproductive health, zinc participates in insulin storage and secretion, insulin‑signal transduction, and ovarian and androgen metabolism.

In women with polycystic ovary syndrome (PCOS), several randomized controlled trials have evaluated zinc supplementation. In one 8‑week double‑blind trial, 50 mg/day elemental zinc significantly improved fasting glucose, insulin, HOMA‑IR, and triglycerides compared with placebo in PCOS women, indicating a beneficial effect on insulin resistance and lipid profile ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25868059/?utm_source=openai)). A separate RCT in PCOS women showed that the same zinc dose reduced alopecia and hirsutism scores and lowered malondialdehyde (an oxidative‑stress marker), suggesting additional roles in redox balance and androgen‑related symptoms ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26315303/?utm_source=openai)).

Why include it in this formula? The “Inositol - 120” product combines myo‑inositol, D‑chiro‑inositol, omega‑3 powder, magnesium glycinate, zinc, and vitamin D3. This constellation clearly targets insulin sensitivity, cardiometabolic health, and cycle or reproductive balance—especially relevant in contexts like PCOS. Within this architecture, zinc citrate is the "trace‑element cofactor" pillar. While myo‑ and D‑chiro‑inositol address insulin second‑messenger pathways and ovarian steroidogenesis, zinc supports pancreatic insulin synthesis and secretion, modulates insulin signaling, and contributes to antioxidant defense in insulin‑resistant states ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25868059/?utm_source=openai)).

Co‑supplementation studies using magnesium‑zinc‑calcium‑vitamin D in PCOS women have shown improvements in fasting insulin, HOMA‑IR, and markers of cardiometabolic risk versus placebo, reinforcing zinc’s place alongside magnesium and vitamin D3 in metabolic support formulas ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29137465/?utm_source=openai)). In this product, zinc citrate helps ensure that improvements driven by inositols and omega‑3s occur in a micronutrient environment that is adequate for optimal insulin action, antioxidant enzyme activity, and hormone‑related tissue function, aligning with the overall goal of restoring metabolic and reproductive balance.

What is this ingredient? Vitamin D3 (cholecalciferol) is a fat‑soluble vitamin and prohormone that the body can synthesize in the skin from sunlight or obtain from food and supplements. After hepatic and renal activation to 1,25‑dihydroxyvitamin D, it binds the vitamin D receptor (VDR) to regulate genes involved in calcium and phosphate balance, immune modulation, and cell growth and differentiation. Low 25‑hydroxyvitamin D levels are common in people with obesity, insulin resistance, and polycystic ovary syndrome (PCOS) and have been associated with adverse metabolic profiles in observational work.

Randomized controlled trials in vitamin‑D–deficient women with PCOS show that cholecalciferol supplementation can modestly improve some metabolic markers. In one 8‑week RCT using 50,000 IU/week in vitamin‑D–deficient PCOS women, vitamin D significantly reduced fasting plasma glucose and increased adiponectin and β‑cell function versus placebo [2]. Another 12‑week RCT in PCOS women with deficiency or insufficiency (2,000 IU/day) reported reductions in BMI, waist‑to‑hip ratio, insulin levels, HOMA‑IR, and triglycerides and LDL‑cholesterol compared with controls [3]. However, not all trials find broad metabolic benefits; some show improved 25(OH)D with only selective changes in glucose dynamics [0,9].

Why include it in this formula? The “Inositol - 120” product combines myo‑inositol, D‑chiro‑inositol, omega‑3 powder, magnesium glycinate, zinc, and vitamin D3. This profile clearly targets insulin sensitivity, cardiometabolic health, and frequently, cycle or PCOS‑related concerns. Within this architecture, vitamin D3 is the "endocrine and metabolic" pillar. It supports insulin sensitivity and body‑composition changes in obese or insulin‑resistant individuals when combined with lifestyle measures, as seen in a double‑blind RCT where cholecalciferol plus weight‑loss significantly improved clamp‑measured insulin sensitivity versus placebo [8].

In PCOS‑focused trials, higher‑dose vitamin D (e.g., 4,000 IU/day) has also improved androgen indices (total testosterone, free androgen index), hs‑CRP, and hirsutism scores compared with lower doses or placebo, suggesting benefits for both metabolic and hyperandrogenic features in this population [4]. In this formula, vitamin D3 works alongside inositols (insulin second messengers), magnesium and zinc (insulin and reproductive cofactors), and omega‑3s (inflammatory tone and lipids) to create a more favorable hormonal and metabolic environment. Rather than acting alone, cholecalciferol helps ensure that the improved signaling driven by inositols occurs in a vitamin‑D‑replete, endocrine‑balanced system, consistent with modern PCOS and insulin‑resistance management strategies.

References

• [0] Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial
• [2] The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial
• [3] Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial
• [4] Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome
• [8] Effect of Vitamin D Supplementation on Obesity-Induced Insulin Resistance: A Double-Blind, Randomized, Placebo-Controlled Trial